MX2017015238A - Composicion oral de celecoxib para tratamiento de dolor. - Google Patents
Composicion oral de celecoxib para tratamiento de dolor.Info
- Publication number
- MX2017015238A MX2017015238A MX2017015238A MX2017015238A MX2017015238A MX 2017015238 A MX2017015238 A MX 2017015238A MX 2017015238 A MX2017015238 A MX 2017015238A MX 2017015238 A MX2017015238 A MX 2017015238A MX 2017015238 A MX2017015238 A MX 2017015238A
- Authority
- MX
- Mexico
- Prior art keywords
- celecoxib
- pain
- treatment
- oral composition
- relates
- Prior art date
Links
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 title abstract 4
- 229960000590 celecoxib Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 239000012530 fluid Substances 0.000 abstract 1
- 230000002496 gastric effect Effects 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 238000001556 precipitation Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000003756 stirring Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención se relaciona a una composición farmacéutica líquida oral estable de celecoxib o sus sales farmacéuticamente aceptables del mismo. El celecoxib presente en las composiciones como es descrito en la presente no muestra alguna precipitación cuando se somete en Fluido Gástrico Simulado en Estado en Ayunas (FaSSGF) en pH 2.0, temperatura de 37°C ± 0.5°C y bajo agitación a una velocidad de 50 rpm por lo menos durante 60 minutos. También se relaciona al proceso para preparar y el método para utilizar la composición de celecoxib.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IN2682CH2015 | 2015-05-28 | ||
IN6614CH2015 | 2015-12-10 | ||
PCT/US2016/034844 WO2016191744A1 (en) | 2015-05-28 | 2016-05-27 | Oral composition of celecoxib for treatment of pain |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017015238A true MX2017015238A (es) | 2018-02-19 |
Family
ID=56137539
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015238A MX2017015238A (es) | 2015-05-28 | 2016-05-27 | Composicion oral de celecoxib para tratamiento de dolor. |
Country Status (13)
Country | Link |
---|---|
US (7) | US9572819B2 (es) |
EP (1) | EP3302429A1 (es) |
JP (1) | JP6605047B2 (es) |
KR (1) | KR101994129B1 (es) |
CN (3) | CN117547528A (es) |
AU (2) | AU2016267685A1 (es) |
BR (1) | BR112017025445A2 (es) |
CA (1) | CA2987272C (es) |
EA (1) | EA038013B1 (es) |
MX (1) | MX2017015238A (es) |
NZ (1) | NZ737561A (es) |
RU (1) | RU2708254C2 (es) |
WO (1) | WO2016191744A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3302429A1 (en) * | 2015-05-28 | 2018-04-11 | Dr. Reddy's Laboratories Ltd. | Oral composition of celecoxib for treatment of pain |
AU2017275844A1 (en) * | 2016-05-27 | 2019-01-17 | Dr. Reddy's Laboratories Ltd. | Oral composition of celecoxib for treatment of pain |
US11018667B2 (en) | 2018-01-05 | 2021-05-25 | Darfon Electronics Corp. | Optical keyswitch |
US11770123B2 (en) | 2018-01-05 | 2023-09-26 | Darfon Electronics Corp. | Optical keyswitch comprising a keycap having a light transmission area and a keycap projection area projected on a circuit board |
EP4267132A1 (en) * | 2020-12-28 | 2023-11-01 | Dr. Reddy's Laboratories Ltd. | Celecoxib for treating pain |
US11721500B2 (en) | 2021-04-07 | 2023-08-08 | Darfon Electronics Corp. | Keyswitch assembly and support mechanism thereof |
US11735379B2 (en) | 2021-04-07 | 2023-08-22 | Darfon Electronics Corp. | Keyswitch assembly |
Family Cites Families (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE159426T1 (de) | 1991-04-16 | 1997-11-15 | Nippon Shinyaku Co Ltd | Verfahren zur herstellung einer festen dispersion |
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
ATE212985T1 (de) | 1993-11-30 | 2002-02-15 | Searle & Co | Tricyclische,substituierte pyrazolyl- benzolsulfonamide und ihre verwendung als cyclooxygenase ii inhibitoren |
GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
NZ502567A (en) | 1997-07-29 | 2002-03-28 | Upjohn Co | Self-emulsifying formulation for lipophilic compounds containing a pyranone and a mixture of monoglycerides and diglycerides |
AU5486899A (en) | 1998-08-13 | 2000-03-06 | Cima Labs, Inc. | Microemulsions as solid dosage forms for oral administration |
SA99191255B1 (ar) * | 1998-11-30 | 2006-11-25 | جي دي سيرل اند كو | مركبات سيليكوكسيب celecoxib |
PL348193A1 (en) | 1998-12-11 | 2002-05-06 | Pharmasolutions | Self-emulsifying compositions for drugs poorly soluble in water |
US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
US6761903B2 (en) | 1999-06-30 | 2004-07-13 | Lipocine, Inc. | Clear oil-containing pharmaceutical compositions containing a therapeutic agent |
US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
US6383471B1 (en) * | 1999-04-06 | 2002-05-07 | Lipocine, Inc. | Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents |
US6057289A (en) | 1999-04-30 | 2000-05-02 | Pharmasolutions, Inc. | Pharmaceutical composition comprising cyclosporin in association with a carrier in a self-emulsifying drug delivery system |
US6720001B2 (en) | 1999-10-18 | 2004-04-13 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
SK12682001A3 (sk) * | 1999-12-08 | 2002-07-02 | Pharmacia Corporation, Corporate Patent Department | Celecoxib v tuhej forme so zvýšenou biologickou dostupnosťou |
SK12672001A3 (sk) * | 1999-12-08 | 2002-04-04 | Pharmacia Corporation | Zloženia inhibítora cyklooxygenázy-2 s rýchlym nástupom terapeutického účinku |
AU2001251650A1 (en) | 2000-04-18 | 2001-10-30 | Pharmacia Corporation | Rapid-onset formulation of a selective cyclooxigenase-2 |
US20080009467A1 (en) * | 2000-05-01 | 2008-01-10 | Accera, Inc. | Combinations of medium chain triglycerides and therapeutic agents for the treatment and prevention of alzheimers disease and other diseases resulting from reduced neuronal metabolism |
MY120279A (en) | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
BR0114969A (pt) | 2000-10-31 | 2003-12-09 | Boehringer Ingelheim Pharma | Formulações de emulsificação própria de dosagem oral de inibidores de piranona protease |
BR0210505A (pt) | 2001-06-21 | 2004-05-18 | Pfizer Prod Inc | Formulações auto-emulsionantes de inibidores da proteìna de transferência de ésteres de colesterilo |
US20030073609A1 (en) * | 2001-06-29 | 2003-04-17 | Pinkerton Thomas C. | Enhanced pharmacokinetic profile of intradermally delivered substances |
IL164163A0 (en) | 2002-04-09 | 2005-12-18 | Pharmacia Corp | Process for preparing a finely self-emulsifiable pharmaceutical composition |
US6689382B2 (en) * | 2002-05-15 | 2004-02-10 | Procaps S.A. | Soft shell gelatin capsules containing non-steroidal anti-inflammatories |
EP1515703A1 (en) | 2002-06-21 | 2005-03-23 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US20060148877A1 (en) | 2002-11-26 | 2006-07-06 | Transform Pharmaceuticals, Inc. | Pharmaceutical formulations of celcoxib |
JP4994039B2 (ja) | 2003-11-26 | 2012-08-08 | スパーナス ファーマシューティカルズ インコーポレイテッド | 脂溶性または疎水性化合物の送達に有用なミセル系 |
CN101410012A (zh) | 2006-03-28 | 2009-04-15 | 杰佛林制药公司 | 低剂量的非甾体抗炎药和β-环糊精的制剂 |
EP1961412A1 (en) | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Self-microemulsifying drug delivery systems |
WO2008115572A1 (en) | 2007-03-21 | 2008-09-25 | Theraquest Biosciences, Inc. | Methods and compositions of nsaids |
US20100233272A1 (en) * | 2007-11-15 | 2010-09-16 | Leah Elizabeth Appel | Dosage forms comprising celecoxib providing both rapid and sustained pain relief |
WO2010150144A2 (en) * | 2009-06-25 | 2010-12-29 | Wockhardt Research Centre | Low dose pharmaceutical compositions of celecoxib |
EP2311446A1 (en) * | 2009-10-16 | 2011-04-20 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising Tramadol and Celecoxib in the treatment of pain |
EP2340819A1 (en) * | 2009-12-23 | 2011-07-06 | Laboratorios Del. Dr. Esteve, S.A. | Compositions comprising venlafaxine and celecoxib in the treatment of pain |
US9415035B2 (en) * | 2010-09-17 | 2016-08-16 | Maine Natural Health Company, Inc. | Compositions containing omega-3 oil with an anti-inflammatory agent and uses thereof |
KR101413846B1 (ko) * | 2012-04-12 | 2014-06-30 | 주식회사 종근당 | 4-[5-(4-메칠페닐)-3-(트리플루오로메칠)피라졸-1-일]벤젠술폰아미드 화합물 함유 액상 조성물 |
KR101455901B1 (ko) * | 2012-05-04 | 2014-11-03 | 성균관대학교산학협력단 | 세레콕시브 및 폴록사머를 포함하는 공융 혼합물 |
KR20140100170A (ko) | 2013-02-05 | 2014-08-14 | 에스케이케미칼주식회사 | 셀레콕시브 경구투여용 조성물 |
MX349193B (es) | 2013-08-27 | 2017-07-18 | Alparis Sa De Cv | Capsula con contenido liquido con un antiinflamatorio. |
EP3104840B8 (en) | 2014-02-11 | 2019-07-10 | Latitude Pharmaceuticals Inc. | Parenteral compositions of celecoxib |
US20150342893A1 (en) * | 2014-05-29 | 2015-12-03 | Sigmoid Pharma Limited | Celecoxib formulations useful for treating colorectal cancer |
EP3302429A1 (en) * | 2015-05-28 | 2018-04-11 | Dr. Reddy's Laboratories Ltd. | Oral composition of celecoxib for treatment of pain |
RU2017145602A (ru) * | 2015-05-29 | 2019-07-02 | Кил Лэборетериз, Инк. | Жидкие композиции целекоксиба для перорального введения |
-
2016
- 2016-05-27 EP EP16730581.2A patent/EP3302429A1/en active Pending
- 2016-05-27 AU AU2016267685A patent/AU2016267685A1/en not_active Abandoned
- 2016-05-27 EA EA201792530A patent/EA038013B1/ru unknown
- 2016-05-27 MX MX2017015238A patent/MX2017015238A/es unknown
- 2016-05-27 JP JP2017561947A patent/JP6605047B2/ja active Active
- 2016-05-27 CN CN202311387716.7A patent/CN117547528A/zh active Pending
- 2016-05-27 CN CN202111630363.XA patent/CN114209707A/zh active Pending
- 2016-05-27 KR KR1020177035928A patent/KR101994129B1/ko active IP Right Grant
- 2016-05-27 NZ NZ737561A patent/NZ737561A/en not_active IP Right Cessation
- 2016-05-27 CA CA2987272A patent/CA2987272C/en active Active
- 2016-05-27 WO PCT/US2016/034844 patent/WO2016191744A1/en active Application Filing
- 2016-05-27 CN CN201680031177.5A patent/CN107847437B/zh active Active
- 2016-05-27 US US15/167,922 patent/US9572819B2/en active Active
- 2016-05-27 RU RU2017144574A patent/RU2708254C2/ru active
- 2016-05-27 BR BR112017025445A patent/BR112017025445A2/pt active Search and Examination
- 2016-12-09 US US15/374,951 patent/US9795620B2/en active Active
-
2017
- 2017-09-22 US US15/712,415 patent/US9949990B2/en active Active - Reinstated
-
2018
- 2018-03-15 US US15/922,353 patent/US10799517B2/en active Active
- 2018-03-15 US US15/922,170 patent/US10376527B2/en active Active
-
2019
- 2019-03-29 US US16/369,981 patent/US20190224219A1/en not_active Abandoned
- 2019-05-31 AU AU2019203815A patent/AU2019203815A1/en not_active Abandoned
-
2021
- 2021-09-10 US US17/471,858 patent/US20220241298A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017015238A (es) | Composicion oral de celecoxib para tratamiento de dolor. | |
EP4292650A3 (en) | Heterocyclic compounds as immunomodulators | |
EP4292588A3 (en) | Administration of deuterated cftr potentiators | |
EP4275748A3 (en) | Compositions and methods for treating cns disorders | |
MX2018003569A (es) | Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos. | |
EA201890449A1 (ru) | Фумагиллиновые гетероциклические соединения и способы их получения и применения | |
EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
NZ734400A (en) | Amide compounds as 5-ht4 receptor agonists | |
MX2015001917A (es) | Composiciones farmaceuticas de memantina. | |
WO2016199076A3 (en) | Polymorphic forms of afatinib free base and afatinib dimaleate | |
NZ737892A (en) | Muscarinic m1 receptor positive allosteric modulators | |
PH12016501519A1 (en) | Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions | |
MY192813A (en) | Aqueous formulation comprising paracetamol and ibuprofen | |
NZ740587A (en) | Fluoroindole derivatives as muscarinic m1 receptor positive allosteric modulators | |
WO2016005962A3 (en) | Stable liquid formulations of cyclophosphamide and processes | |
WO2016015798A9 (en) | Orodispersible film composition comprising enalapril for the treatment of hypertension in a pediatric population | |
WO2017208069A3 (en) | Oral composition of celecoxib for treatment of pain | |
EP3626712A3 (en) | Liver x receptor (lxr) modulators | |
WO2015001541A3 (en) | Pharmaceutical film composition | |
MX2019008554A (es) | Moduladores de los receptores a3 de adenosina. | |
EP3881845A3 (en) | Combination of trazodone and gabapentin for the treatment of pain | |
IN2014MU01178A (es) | ||
PH12019502792A1 (en) | Tetrahydropyridopyrazine modulators of gpr6 | |
IN2014MU01179A (es) | ||
MX2016017336A (es) | Uso de acido bisfosfonico y sus sales en la preparacion de composiciones utiles en el tratamiento de la osteoporosis. |